Gucci Belt For Men Black
GlaxoSmithKline (GSK) (JOBS), AFFiRiS GmbH Ink $553 Million Alzheimer Vaccine Deal Vical Incorporated (VICL) to Receive More Shareholder Investment
Vienna based AFFiRiS AG today announced that its atherosclerosis vaccine development program is receiving support from the EU's EUROTRANS BIO call. The supported project known as CETP Vaccine (ETB 2008 28) is based on the AFFITOME(R) technology of AFFiRiS AG and is being conducted together with EMC microcollections GmbH from Tubingen, Germany. The urgent need for an effective strategy against atherosclerosis is clearly evident from the Gucci Belt Red Snake
AFFiRiS GmbH Begins Development of a Parkinson's Vaccine Array BioPharma, Inc. (ARRY) Gets Additional $40 Million Funding
as demonstrated by the licensing agreement worth EUR 430 million that we recently concluded with GSK Biologicals regarding the rights for the technology for our Alzheimer's vaccine programs."
AFFiRiS GmbH Atherosclerosis Vaccine Development Receives EU Support
The CETP Vaccine project is scheduled to last 30 months and is due to culminate in phase I clinical trials. Overall, the support provided to the project by the EU is worth several hundred thousand euros, while the two project partners are bearing around half of the total costs.
MIG Fonds Increases Investment in AFFiRiS GmbH by Euro 3 Million Spectrum Pharmaceuticals, Inc. (SPPI) to Raise $20 Million from Institutional Investors at $5.11 Per Share, the Closing Bid Price on Tuesday, May 26, 2009
About AFFiRiS AG (as at May 2009):
CEO Dr. Walter Schmidt continues: "So far, we have announced the development of vaccines for three diseases Alzheimer's, Parkinson's and now atherosclerosis. Currently, four other indications are also part of our development pipeline, all of them characterised by a very high number of patients but also by a lack of satisfactory treatments. As a result, these indications fit in well with our long term strategy. Our strategy itself is beginning to pay back Louis Vuitton Belt Black
VIENNA, Austria, May 27 /PRNewswire/ The atherosclerosis vaccine development program by AFFiRiS AG is receiving financial support from the Ferragamo Belt Gold Buckle
Outlining the major benefit of the AFFITOME(R) technology, project manager Dr. Sylvia Brunner adds: "CETP is one of the body's own proteins. Trying to reduce its activity using a vaccine, we are faced with a formidable challenge. The body has many means of suppressing an immune response to its own proteins, or limiting the effectiveness of any such response. That's why previous attempts to develop a vaccine against CETP failed. However, as AFFiRiS has already demonstrated in its work on a vaccine for Alzheimer's disease, the AFFITOME(R) technology makes it possible to circumvent these mechanisms. We are now applying this principle to atherosclerosis."
AFFiRiS GmbH Milestone Reached in Clinical Trial of Alzheimer's Vaccine GlaxoSmithKline (GSK) Offers World Health Organization 50 Million Pandemic Vaccines
AFFiRiS AG develops customised peptide based vaccines based on its own patents. These are used to treat Alzheimer's disease, atherosclerosis, Parkinson's disease and other diseases that urgently require a medical solution and for which the market volumes are highly attractive. Alzheimer's disease is currently the foremost indication and two potential products are in the final stages of clinical phase I studies. In October 2008, the company succeeded in gaining GlaxoSmithKline Biologicals as its licensing partner for the Alzheimer's vaccine. The contract foresees payments of up to EUR 430 million (these payments are dependent on certain milestones). AFFiRiS currently employs 50 highly qualified staff and recently acquired an additional 1,100 square meters of premises at the St.
EU's EUROTRANS BIO call. The respective project is being carried out in cooperation with German company EMC microcollections GmbH. The aim of atherosclerosis vaccination is to increase the amount of "good" high density lipoprotein cholesterol (HDLc) in the blood and thus reduce the occurrence of harmful fatty deposits in the arteries. Product candidates were delivered by AFFiRiS' AFFITOME(R) platform technology. The target is a protein known as CETP (cholesteryl ester transfer protein). Following vaccines for Alzheimer's disease and Parkinson's disease, the atherosclerosis vaccine is the third such project announced by AFFiRiS AG.
CSO Dr. Frank Mattner explains: "Today's therapies with Statins act on low density lipoprotein cholesterol (LDLc) and reduce its concentration in the blood. This type of treatment can reduce the likelihood of severe heart disease by as little as 30 % and that's only if the patient takes the necessary medication correctly and regularly. In contrast, our Gucci Belt For Men Black vaccine approach aims at decreasing the cholesterol transfer from HDL to LDL, thus increasing the concentration of the beneficial HDL. This vaccine approach with its long lasting effects should avoid patients having to take life long, daily medication to a strict regimen."
CONTACT: Contact at AFFiRiS AG: Agnes Meyer, T +43 1 798 15 75 390, ERelations for Research Education, Campus Vienna Biocenter 2, TRelated News
The main item of the joint efforts of AFFiRiS and EMC is the vaccination against cholesteryl ester transfer protein (CETP). By transferring cholesteryl ester from HDLc to LDLc and VLDLc, this protein reduces "good" HDL and has a detrimental impact on the ratio of LDLc to HDLc. In the future, our vaccine will reduce the activity of this protein and shift the balance of HDLc and LDLc in the blood back in favour of HDLc.
relevant figures diseases of the cardiovascular system are the number one cause of death in Europe and the US. In Europe, this is at the root of almost 50 % of all deaths. One of the primary causes of cardiovascular disease is atherosclerosis, a narrowing of key arteries due to fatty deposits. Although there are options for medication based intervention in the form of statins, these are deemed to be of limited effectiveness despite some notable successes.
Gucci Belt For Men Black
Lv Belt Men
Adidas Cap Design
Chicago Bulls Cap Snapback
Lv Belt Brown
Hermes Belt Black And Brown Reversible
New Era Florida Panthers
Hermes Belt Women Black
Jordan Hats For Boys
Louis Vuitton Belts Black
Gucci Belt Snake Gg
Lv Belts Online
Hermes Belt Diamond
Jordan Hat Snapback
Versace Belt Womens